1283 related articles for article (PubMed ID: 22119441)
1. Intranasal delivery of biologics to the central nervous system.
Lochhead JJ; Thorne RG
Adv Drug Deliv Rev; 2012 May; 64(7):614-28. PubMed ID: 22119441
[TBL] [Abstract][Full Text] [Related]
2. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
Begley DJ
Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
[TBL] [Abstract][Full Text] [Related]
3. Prodrug approaches to reduce hyperexcitation in the CNS.
Vytla D; Combs-Bachmann RE; Hussey AM; McCarron ST; McCarthy DS; Chambers JJ
Adv Drug Deliv Rev; 2012 May; 64(7):666-85. PubMed ID: 22138074
[TBL] [Abstract][Full Text] [Related]
4. Insights into direct nose to brain delivery: current status and future perspective.
Mittal D; Ali A; Md S; Baboota S; Sahni JK; Ali J
Drug Deliv; 2014 Mar; 21(2):75-86. PubMed ID: 24102636
[TBL] [Abstract][Full Text] [Related]
5. Intranasal drug delivery to the central nervous system: present status and future outlook.
Tayebati SK; Nwankwo IE; Amenta F
Curr Pharm Des; 2013; 19(3):510-26. PubMed ID: 23116337
[TBL] [Abstract][Full Text] [Related]
6. From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery.
Soddu E; Rassu G; Giunchedi P; Sarmento B; Gavini E
Eur J Pharm Sci; 2015 Jul; 74():63-76. PubMed ID: 25892455
[TBL] [Abstract][Full Text] [Related]
7. Delivery of therapeutics to the central nervous system.
Chambers JJ
Adv Drug Deliv Rev; 2012 May; 64(7):589. PubMed ID: 22388004
[No Abstract] [Full Text] [Related]
8. Applications of nanotechnology in drug delivery to the central nervous system.
Saeedi M; Eslamifar M; Khezri K; Dizaj SM
Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991
[TBL] [Abstract][Full Text] [Related]
9. Intranasal delivery to the central nervous system: mechanisms and experimental considerations.
Dhuria SV; Hanson LR; Frey WH
J Pharm Sci; 2010 Apr; 99(4):1654-73. PubMed ID: 19877171
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnological advances for the delivery of CNS therapeutics.
Wong HL; Wu XY; Bendayan R
Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
[TBL] [Abstract][Full Text] [Related]
11. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis.
Ross TM; Martinez PM; Renner JC; Thorne RG; Hanson LR; Frey WH
J Neuroimmunol; 2004 Jun; 151(1-2):66-77. PubMed ID: 15145605
[TBL] [Abstract][Full Text] [Related]
12. Differential receptor-mediated drug targeting to the diseased brain.
Rip J; Schenk GJ; de Boer AG
Expert Opin Drug Deliv; 2009 Mar; 6(3):227-37. PubMed ID: 19327042
[TBL] [Abstract][Full Text] [Related]
13. Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents.
Biddlestone-Thorpe L; Marchi N; Guo K; Ghosh C; Janigro D; Valerie K; Yang H
Adv Drug Deliv Rev; 2012 May; 64(7):605-13. PubMed ID: 22178615
[TBL] [Abstract][Full Text] [Related]
14. Strategy for effective brain drug delivery.
Alam MI; Beg S; Samad A; Baboota S; Kohli K; Ali J; Ahuja A; Akbar M
Eur J Pharm Sci; 2010 Aug; 40(5):385-403. PubMed ID: 20497904
[TBL] [Abstract][Full Text] [Related]
15. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
Barchet TM; Amiji MM
Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
[TBL] [Abstract][Full Text] [Related]
16. Formulation and physiological factors influencing CNS delivery upon intranasal administration.
Vyas TK; Tiwari SB; Amiji MM
Crit Rev Ther Drug Carrier Syst; 2006; 23(4):319-47. PubMed ID: 17341201
[TBL] [Abstract][Full Text] [Related]
17. Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states.
Deo AK; Theil FP; Nicolas JM
Mol Pharm; 2013 May; 10(5):1581-95. PubMed ID: 23256608
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
[TBL] [Abstract][Full Text] [Related]
19. Targeted drug delivery to central nervous system (CNS) for the treatment of neurodegenerative disorders: trends and advances.
Goyal K; Koul V; Singh Y; Anand A
Cent Nerv Syst Agents Med Chem; 2014; 14(1):43-59. PubMed ID: 25360772
[TBL] [Abstract][Full Text] [Related]
20. Nanobiotechnology-based drug delivery to the central nervous system.
Jain KK
Neurodegener Dis; 2007; 4(4):287-91. PubMed ID: 17627131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
